.jpg "Ultragenyx (NASDAQ: RARE)")
After Piper Jaffray and J.P. Morgan gave Ultragenyx (NASDAQ: RARE) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Ultragenyx today. The company’s shares opened today at $84.10, close to its 52-week high of $90.98.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 31.8% and a 54.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Ultragenyx is a Strong Buy with an average price target of $91.90, which is a 9.3% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $52.73 million. In comparison, last year the company had a GAAP net loss of $72.89 million.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
